"I'm surprised anyone has ever written a prescription for Nexium. ``There was so much denial over there,'' said David Moskowitz, senior pharmaceutical analyst for Friedman, Billings, Ramsey Co. Last week, Gilmartin and Kim still said that none of the earlier Vioxx studies, by either the company or others, convincingly showed increased heart and stroke risk from the drug. Kim, Frazier and Gilmartin gathered in the chief executive's conference room at the Whitehouse Station, N.J., campus. Vioxx was Merck's fourth top seller, and they knew their decision would be extremely harmful to the company.